RECURRENT PYOPNEUMOTHORAX IN MULTI DRUG RESISTANT TUBERCULOSIS PATIENT: A CASE REPORT

Respirology ◽  
2017 ◽  
Vol 22 ◽  
pp. 13-13 ◽  
Keyword(s):  
Case Report ◽  
Tuberculosis Patient ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis

scholarly journals Pulmonary rehabilitation in multi-drug resistant tuberculosis (TB MDR): a case report

1969 ◽  
Vol 40 (4) ◽  
pp. 436-441
Author(s):  
Esther Cecilia Wilches ◽  
Julián Andrés Rivera ◽  
Ricardo Mosquera ◽  
Liliana Loaiza ◽  
Lucely Obando
Keyword(s):  
Case Report ◽  
Pulmonary Rehabilitation ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis

scholarly journals A home-based approach to managing multi-drug resistant tuberculosis in Uganda: A case report

2012 ◽  
Vol 9 (1) ◽  
pp. 12 ◽  
Author(s):  
Emmanual Luyirika ◽  
Henry Nsobya ◽  
Richard Batamwita ◽  
Pheona Busingye ◽  
William Musoke ◽  
...  
Keyword(s):  
Case Report ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Home Based ◽  
Multi Drug Resistant Tuberculosis

scholarly journals Ototoxic effect of anti-tubercular treatment on multi-drug resistant tuberculosis patient

2019 ◽  
Vol 6 (1) ◽  
pp. 8
Author(s):  
Sachin Jain ◽  
M. Aftab ◽  
Shivendra Pratap Singh ◽  
Abhishek Kumar Dubey ◽  
Ved Prakash Upadhyay ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Pure Tone Audiometry ◽  
Control Program ◽  
Tuberculosis Patient ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis ◽  
Mdr Tb

<p class="abstract"><strong>Background:</strong> Multi-drug resistant tuberculosis (MDR-TB) is defined as tuberculosis caused by <em>Mycobacterium tuberculosis</em> resistant in vitro to the effects of isoniazid and rifampicin, with or without resistance to any other drugs. Regimen for MDR-TB<strong> </strong>comprises of 6 drugs - kanamycin, levofloxacin, ethionamide, pyrazinamide, ethambutol and cycloserine during 6-9 months of the intensive phase and 4 drugs levofloxacin, ethionamide, ethambutol and cycloserine during the 18 months of the continuation phase. The aim of our study was to document the incidence and severity of ototoxicity in MDR-TB patient receiving category IV treatment under the revised national tuberculosis control program.</p><p class="abstract"><strong>Methods:</strong> Prospective cohort study was carried out on proven case of MDR-TB patients. Total 61 patients were evaluated for the development of ototoxicity, for a period of one year. First three months of study pre-treatment baseline audiogram were recorded by pure tone audiometry, and repeat audiogram was done after six months and nine months.  </p><p class="abstract"><strong>Results:</strong> Out of 61 patients 21 patients developed ototoxicity with incidence of 34.42%. Incidence of high frequency hearing loss was 21.31% and flat loss was 13.11%.</p><p class="abstract"><strong>Conclusions:</strong> MDR-TB patients, due to effect of aminoglycoside may develop mild to severe degree of hearing loss. As hearing loss in these patients is permanent, careful audiological monitoring should be done regularly.</p><p class="abstract"> </p>

Sign in / Sign up

Export Citation Format

Share Document